ovarian cancer
Conditions
Interventions
Case series:Anlotinib combined with Pemetrexed
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histological or pathological confirmed diagnosis of epithelial carcinoma of the ovary, fallopian tube, or peritoneal; 2. Platinum-resistant ovarian cancer (defined as relapsing within 12 months after the last administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing while on a platinum-based chemotherapy), at least treated with one line of platinum-based chemotherapy,or at least treated with two different regimens of chemotherapy ; 3. Female aged 18 to 70 years, signed informed consent; 4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version; 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 6. Patients must have a life expectancy of at least 3 months; 7. Patients must have adequate organ function as defined by the following criteria:White blood cell count = 3 x 10^9/L, Absolute neutrophil count (ANC) (= 1.5 x 10^9/L), Hemoglobin of = 80 g/L, Platelets = 70 x 10^9/L; Total bilirubin = 1 x upper limit of normal (ULN), AST and ALT = 2 x ULN;Serum creatinine = 1 x ULN.
Exclusion criteria
Exclusion criteria: 1. Had prior exposure to anlotinib or has known allegic to any of the excipients; 2. Patients with QT interval prolongation; 3. History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1; 4. History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1; 5. Evidence of bleeding diathesis or coagulopathy; 6. Inadequately controlled hypertension; 7. Major surgical procedure within 28 days prior to Day 1; 8. Symptomatic central nervous system (CNS) metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Duration of Response; | — |
Countries
China
Contacts
Public ContactZhang Yanna
Sun Yat-sen University Cancer Center
Outcome results
None listed